Inoviq Ltd - Asset Resilience Ratio

Latest as of December 2025: 56.29%

Inoviq Ltd (IIQ) has an Asset Resilience Ratio of 56.29% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Inoviq Ltd for a breakdown of total debt and financial obligations.

Liquid Assets

AU$13.80 Million
≈ $9.76 Million USD Cash + Short-term Investments

Total Assets

AU$24.52 Million
≈ $17.35 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (1993–2025)

This chart shows how Inoviq Ltd's Asset Resilience Ratio has changed over time. See IIQ net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Inoviq Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Inoviq Ltd.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$13.80 Million 56.29%
Short-term Investments AU$0.00 0%
Total Liquid Assets AU$13.80 Million 56.29%

Asset Resilience Insights

  • Very High Liquidity: Inoviq Ltd maintains exceptional liquid asset reserves at 56.29% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Inoviq Ltd Industry Peers by Asset Resilience Ratio

Compare Inoviq Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Revvity Inc.
NYSE:RVTY
Diagnostics & Research 0.00%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Fleury S.A.
SA:FLRY3
Diagnostics & Research 16.19%
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060
Diagnostics & Research 2.10%
Genoray Co. Ltd
KQ:122310
Diagnostics & Research 0.03%
Bcal Diagnostics Ltd
AU:BDX
Diagnostics & Research 0.00%
Avricore Health Inc
V:AVCR
Diagnostics & Research 0.75%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%

Annual Asset Resilience Ratio for Inoviq Ltd (1993–2025)

The table below shows the annual Asset Resilience Ratio data for Inoviq Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 35.33% AU$6.52 Million
≈ $4.61 Million
AU$18.46 Million
≈ $13.06 Million
-7.21pp
2024-06-30 42.54% AU$9.23 Million
≈ $6.53 Million
AU$21.71 Million
≈ $15.36 Million
+6.22pp
2023-06-30 36.32% AU$7.81 Million
≈ $5.53 Million
AU$21.51 Million
≈ $15.22 Million
-13.69pp
2022-06-30 50.02% AU$15.39 Million
≈ $10.89 Million
AU$30.78 Million
≈ $21.78 Million
+35.11pp
2021-06-30 14.91% AU$5.00 Million
≈ $3.54 Million
AU$33.52 Million
≈ $23.72 Million
-84.45pp
2020-06-30 99.36% AU$7.33 Million
≈ $5.18 Million
AU$7.37 Million
≈ $5.22 Million
+0.27pp
2019-06-30 99.08% AU$7.56 Million
≈ $5.35 Million
AU$7.63 Million
≈ $5.40 Million
-0.40pp
2018-06-30 99.49% AU$1.45 Million
≈ $1.02 Million
AU$1.45 Million
≈ $1.03 Million
+98.71pp
2016-06-30 0.78% AU$25.65K
≈ $18.15K
AU$3.29 Million
≈ $2.33 Million
+0.58pp
2015-06-30 0.20% AU$3.62K
≈ $2.56K
AU$1.85 Million
≈ $1.31 Million
+0.06pp
2014-06-30 0.14% AU$3.89K
≈ $2.75K
AU$2.82 Million
≈ $2.00 Million
-2.98pp
2013-06-30 3.12% AU$131.65K
≈ $93.15K
AU$4.23 Million
≈ $2.99 Million
+2.06pp
2012-06-30 1.06% AU$172.15K
≈ $121.80K
AU$16.29 Million
≈ $11.53 Million
-1.97pp
2011-06-30 3.02% AU$811.50K
≈ $574.19K
AU$26.85 Million
≈ $19.00 Million
+1.19pp
2010-06-30 1.83% AU$358.99K
≈ $254.01K
AU$19.60 Million
≈ $13.87 Million
-0.56pp
2009-06-30 2.39% AU$477.55K
≈ $337.90K
AU$19.96 Million
≈ $14.13 Million
-9.46pp
2008-06-30 11.86% AU$727.10K
≈ $514.47K
AU$6.13 Million
≈ $4.34 Million
+11.84pp
2005-06-30 0.02% AU$2.63K
≈ $1.86K
AU$17.44 Million
≈ $12.34 Million
-0.16pp
2004-06-30 0.17% AU$6.10K
≈ $4.32K
AU$3.50 Million
≈ $2.48 Million
-4.28pp
2003-06-30 4.46% AU$118.68K
≈ $83.98K
AU$2.66 Million
≈ $1.88 Million
-17.54pp
2002-06-30 22.00% AU$631.88K
≈ $447.09K
AU$2.87 Million
≈ $2.03 Million
+21.77pp
1999-06-30 0.23% AU$21.66K
≈ $15.33K
AU$9.47 Million
≈ $6.70 Million
+0.14pp
1998-06-30 0.08% AU$9.80K
≈ $6.93K
AU$11.57 Million
≈ $8.18 Million
-1.27pp
1997-06-30 1.36% AU$153.49K
≈ $108.60K
AU$11.33 Million
≈ $8.01 Million
-4.67pp
1996-06-30 6.02% AU$688.76K
≈ $487.34K
AU$11.44 Million
≈ $8.09 Million
+0.40pp
1995-06-30 5.62% AU$591.00K
≈ $418.17K
AU$10.51 Million
≈ $7.44 Million
-0.48pp
1994-06-30 6.10% AU$641.00K
≈ $453.55K
AU$10.50 Million
≈ $7.43 Million
-8.68pp
1993-06-30 14.79% AU$346.00K
≈ $244.82K
AU$2.34 Million
≈ $1.66 Million
--
pp = percentage points

About Inoviq Ltd

AU:IIQ Australia Diagnostics & Research
Market Cap
$32.37 Million
AU$45.75 Million AUD
Market Cap Rank
#23468 Global
#930 in Australia
Share Price
AU$0.33
Change (1 day)
+0.00%
52-Week Range
AU$0.32 - AU$0.57
All Time High
AU$4.10
About

INOVIQ Ltd develops and commercializes diagnostic and exosome-based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non… Read more